A multidisciplinary team developed a Mindfulness-Based Stress Reduction (MBSR) program specifically for Chinese patients with hematologic malignancies. Through a literature review and two rounds of Delphi expert consultations involving 30 experts (15 in hematology and 15 in psychology), the protocol was refined to include 2 primary, 9 secondary, and 27 tertiary items. Expert authority coefficients rose from 0.846 to 0.875 across rounds, indicating growing consensus. The standardized program aims to provide psychological support and physiological adjustment strategies for these patients and offers a practical protocol for integration into clinical and psychosocial oncology care in China.
A double-blinded, placebo-controlled randomized trial tested whether nitrous oxide (N2O) improves cognitive function in 44 patients with treatment-resistant depression. Thirty-four patients completed cognitive tests before treatment and at 1 and 2 weeks after a one-hour inhalation of 50% N2O/50% oxygen or placebo (50% air/50% oxygen). Although N2O did not produce a significant antidepressant effect at 1 week, patients who received N2O showed better executive function at 1 week compared with placebo, and this improvement remained after controlling for changes in depressive symptoms. No significant differences were found in subjective cognitive function, processing speed, or attention over the 2-week follow-up. The results suggest N2O may have a pro-cognitive effect on executive function independent of mood improvement.
A single one-hour inhalation of 50% nitrous oxide (N2O) mixed with oxygen rapidly alleviated depression in patients with treatment-resistant depression in China, but the effect lasted no more than one week. In a double-blind, placebo-controlled trial, 44 patients were randomized to receive either 50% N2O or a placebo mixture. Depression scores on the Hamilton Depression Rating Scale were significantly lower in the N2O group at two hours and 24 hours after treatment, but no significant difference remained at one week or two weeks. Patients receiving N2O reported more adverse events, all of which resolved within 24 hours, and no serious adverse events occurred.